4 June 2008
The European Medicines Agency (EMEA) has recommended the immediate
implementation of changes to the product information for Neupro
(rotigotine), from Schwarz Pharma Ltd, stating that it must be stored in
a refrigerator (at a temperature of between 2ºC and 8ºC).
The new storage conditions are intended to reduce the possible
occurrence of crystallisation of the active substance which has been
reported in patches of Neupro.
Neupro is a centrally-authorised medicine used for the treatment of
Parkinson’s disease. Its active substance, rotigotine, is a dopamine
agonist. Neupro is the only medicine for Parkinson’s disease that is
administered as a transdermal patch.
